Ihr Broker

  • DAX 0,70
  • EUR/USD 0,50
  • GOLD 0,30

Nur Spreads

Keine Kommission

Jetzt registrieren

CFDs sind komplexe Instrumente und umfassen aufgrund der Hebelfinanzierung ein hohes Risiko, schnell Geld zu verlieren.

APEIRON Biologics AG, corporate

APEIRON Biologics AG,

12.10.2021 - 08:03:54

APEIRON Biologics commences clinical COVID-19 trial with inhaled APN01

and connect with us on Twitter and LinkedIn.

For further information please contact:

APEIRON Biologics AG Peter Llewellyn-Davies CEO Email: investors@apeiron-biologics.comwww.apeiron-biologics.com

Media and Investor Relations MC Services AG Raimund Gabriel, Andreas Jungfer T +49 89 210 228 0 Email: apeiron@mc-services.eu

FORWARD LOOKING STATEMENTS Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of APEIRON Biologics as of the date of this press release. Such forward-looking statements are neither promises nor guarantees but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.

12.10.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

1239801??12.10.2021?

@ dgap.de